IPP Bureau
Briefs: CuraTeQ Biologics, Sigachi Industries and Natural Capsules
By IPP Bureau - December 28, 2025
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
Zota Health Care raises Rs 350 crores through QIP issue
By IPP Bureau - December 28, 2025
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
InnoCare Pharma gets green light for Phase II trial of oral lupus drug
By IPP Bureau - December 27, 2025
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Ginkgo Bioworks teams with Carnegie Mellon on cancer detection program
By IPP Bureau - December 27, 2025
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
FDA setback for Sanofi’s Tolebrutinib in progressive MS
By IPP Bureau - December 27, 2025
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Health Minister Nadda to launch Indian Pharmacopoeia 2026 in the first week of Jan. 2026
By IPP Bureau - December 27, 2025
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
WHO report reveals stark global inequities in genomic research
By IPP Bureau - December 27, 2025
EU nod to Wayrilz as breakthrough treatment for hard-to-treat ITP
By IPP Bureau - December 27, 2025
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Chugai’s Tecentriq gets green light in Japan for hard-to-treat Thymic Carcinoma
By IPP Bureau - December 27, 2025
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
Zeon Corporation to acquire Ushio’s microfluidics biz
By IPP Bureau - December 27, 2025
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
Symbiosis rolls out first 10,000 vial batch at Stirling Facility
By IPP Bureau - December 27, 2025
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
IRLAB launches Phase Ib Trial of IRL757 for Parkinson’s patients with Apathy
By IPP Bureau - December 27, 2025
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Amneal and mAbxience score FDA green light for two Denosumab biosimilars
By IPP Bureau - December 27, 2025
Edwards Lifesciences’ SAPIEN M3 becomes first FDA-approved transseptal mitral valve replacement
By IPP Bureau - December 27, 2025
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
Nona Biosciences expands platform to accelerate early clinical trials
By IPP Bureau - December 27, 2025
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
